The combination of CDK4/6 inhibitors with endocrine therapy for estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC) continues to be among ...
Dr. Brian Czerniecki, of Moffitt Cancer Center, led a CURE Educated Patient® Updates in Metastatic Breast Cancer event, and provided subsequent updates. Following a recent CURE Educated Patient® ...
CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...
Metastatic ILC shows significant biomarker heterogeneity, limiting single biopsy reliability and highlighting challenges in detection and monitoring.
Elacestrant (Ela) combinations with ribociclib (Ribo) and everolimus (Eve) in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Update from ELEVATE, a phase (Ph) 1b/2, ...
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (OLMA) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, ...
Low-dose oral minoxidil effectively aids hair regrowth in breast cancer patients post-chemotherapy, with minimal side effects, offering hope for restoring normalcy. Antibody-drug conjugates are ...
Hosted on MSN
Oral drug combination extends progression-free survival in advanced ER-positive breast cancer
Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes ...
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In ...
Dr Fatima Cardoso, director of the Breast Cancer Unit at Champalimaud Cancer Centre in Lisbon, Portugal, is a leader in a global initiative [2] to improve the care and treatment of persons with ...
BERLIN October 18, 2025 – Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results